15 Recruiting Platinum-resistant Ovarian Cancer Clinical Trials
Explore open interventional and observational research studies actively enrolling participants across the USA. Verify eligibility and contact site coordinators directly.
📍 Find Near Me by DistanceBrowse by State
Browse by Study Phase
Top Interventions for Platinum-resistant Ovarian Cancer
Related Conditions
Top Recruiting Platinum-resistant Ovarian Cancer Studies
🔵 Active, Not Recruiting Phase2 / Phase3 💊 Investigational Drug / Biologic
Trial of NP-G2-044 (Prilukae) Combined With PLD for Treatment of Platinum-Resistant Ovarian Cancer (ULTIMUS-1)
📍 HonorHealth Cancer Care — Phoenix, Arizona
View Study & Checklist ➔ 🔵 Active, Not Recruiting Phase3 💊 Investigational Drug / Biologic
Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer
📍 Alaska Women's Cancer Care — Anchorage, Alaska
View Study & Checklist ➔ 🟢 Recruiting Phase1 💊 Investigational Drug / Biologic
A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors
📍 University of Arkansas Winthrop P. Rockefeller Cancer Institute — Little Rock, Arkansas
View Study & Checklist ➔ 🟢 Recruiting Phase2 💊 Investigational Drug / Biologic
A Phase 2, Open-label, Single-arm Study Of Autologous M-CENK Adoptive Cell Therapy And N-803 (IL-15 Superagonist) In Combination With Gemcitabine In Participants With Recurrent Platinum-Resistant High-Grade Ovarian Cancer
📍 Chan Soon-Shiong Institute for Medicine — El Segundo, California
View Study & Checklist ➔ 🟢 Recruiting Phase1 💊 Investigational Drug / Biologic
Intraperitoneal Cytokine-Induced Memory Like (CIML) Natural Killer (NK) Cells in Recurrent Ovarian Cancer
📍 Brigham and Women's Hospital — Boston, Massachusetts
View Study & Checklist ➔ 🟢 Recruiting Phase3 💊 Investigational Drug / Biologic
Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
📍 The University of South Alabama, Mitchell Cancer Institute — Mobile, Alabama
View Study & Checklist ➔ 🟢 Recruiting Phase1 💊 Investigational Drug / Biologic
GB-5267 for the Treatment Platinum-Resistant Ovarian, Peritoneal, or Fallopian Tube Cancer
📍 Roswell Park Comprehensive Cancer Center — Buffalo, New York
View Study & Checklist ➔ 🟢 Recruiting Phase1 💊 Investigational Drug / Biologic
A First-in-Human Study of MEN2501 in Participants With Platinum-Resistant Ovarian Cancer
📍 Highlands Oncology Group — Springdale, Arkansas
View Study & Checklist ➔ 🟢 Recruiting Phase2 💊 Investigational Drug / Biologic
A Study of Lorigerlimab in Participants With Advanced Solid Tumors
📍 UCLA — Los Angeles, California
View Study & Checklist ➔